CSF3 and stroke disorder: These promising findings provide impetus for further exploration of the effects of G-CSF in attenuating delayed tPA-induced outcomes in other experimental stroke models, in line with the Stroke Therapy Academic Industry Roundtable (STAIR) guidelines for clinical development of drug candidates [13], and also for studies to determine the mechanisms of action and long-term effects of the drug, in order to enhance its future clinical application.